Company intelligence / Profile preview

HAGAR

Tel Aviv, Tel Aviv District, Israelredrocker.com ↗

Ownership: Private
Development stage: Preclinical

Overview

GWave has demonstrated >95% accuracy compared to standard finger-prick devices in clinical studies. The device directly measures blood glucose using radiofrequency waves without skin penetration. Pilot studies have shown strong correlation with laboratory assays during oral glucose tolerance tests. Additional pivotal trials are planned or ongoing in Israel and the US. The product has received FDA Breakthrough Device Designation.[3][6][7]

Therapeutic areas: Endocrinology
Modalities: DeviceDigital health technology (non-invasive continuous glucose monitoring)
Industry: Metabolite Diagnostics

Partnerships

Multinational chip manufacturer specializing in RF for mass production of chips

Beyond the preview

Go deeper on HAGAR.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HAGAR.

Explore the full profile